We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Hua Gong Named Executive Director of Medical Diagnostics at Premier Research
News

Hua Gong Named Executive Director of Medical Diagnostics at Premier Research

Hua Gong Named Executive Director of Medical Diagnostics at Premier Research
News

Hua Gong Named Executive Director of Medical Diagnostics at Premier Research

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Hua Gong Named Executive Director of Medical Diagnostics at Premier Research"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Premier Research Group Limited has announced the appointment of Hua Gong to the position of Executive Director of Medical Diagnostics. In this role, Dr. Gong will be responsible for overseeing the In Vitro Diagnostics (IVD) business within the company.

Dr. Gong brings more than 12 years of experience that includes both R&D and clinical expertise in the development of diagnostics.

Her past operational experience within both large and small pharmaceutical companies provides Premier Research with a strong skill set to assist diagnostic companies with product development, regulatory expertise, and clinical trial management.

Prior to joining Premier Research, Dr. Gong was the Associate Director, Medical Diagnostics at Prometheus Therapeutics & Diagnostics where she was responsible for leading the development of companion diagnostics for pharmaceutical companies, overseeing multiple clinical studies to validate their oncology platform as well as contributed to their CEER HER2 510K submission.

Additionally, she worked at Pfizer for 10 years in a variety of positions of increasing responsibility.

In her last position at Pfizer, Dr. Gong served as Principal Scientist, Oncology Exploratory Biology where she managed a multi-disciplinary team including intro/vivo biology, PDM, drug safety and biomarker research groups.

Dr. Gong received a medical degree in preventive medicine from An Hui Medical University in China, a doctorate in cancer biology from Wayne State University in the United States, and a master of sciences in biostatistics from Sun-Yet-Sen University of Medical Sciences.

She has authored more than 15 publications and presentations with a recent focus in oncology and biomarkers.

Bernard Sweeney Vice President, Medical Devices commented, “Hua brings extensive, relevant experience in this fast expanding area having worked with in both the development and commercial sectors of the IVD industry. This business is unique within healthcare and is presently experiencing global changes from regulatory decision makers. It also reflects the move within healthcare to evaluate patient needs and progress through treatment to improve patient outcomes. Together these factors mean that it is necessary for the service provider to be able to meet the specific needs with dedicated resources.”

Advertisement